Klotho Neurosciences, Inc. (KLTO)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on KLTO

With Tiblio's Option Bot, you can configure your own wheel strategy including KLTO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KLTO
  • Rev/Share 0.0
  • Book/Share 0.0232
  • PB 55.1586
  • Debt/Equity 2.768
  • CurrentRatio 0.2942
  • ROIC -2.7735

 

  • MktCap 41592819.0
  • FreeCF/Share -0.1452
  • PFCF -10.4093
  • PE -4.5681
  • Debt/Assets 0.5918
  • DivYield 0
  • ROE -17.7987

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation
KLTO
Published: July 10, 2025 by: Proactive Investors
Sentiment: Positive

Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.

Read More
image for news Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation

About Klotho Neurosciences, Inc. (KLTO)

  • IPO Date
  • Website https://klothoneuro.com
  • Industry Biotechnology
  • CEO Joseph Sinkule
  • Employees 3
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.